Propel treatment forward

For Healthcare Professionals

Propel treatment forward

For unresctable or metastatic liposarcoma or leiomyosarcoma after an anthracycline

YONDELIS® is the only treatment recently approved specifically for unresectable or metastatic liposarcoma or leiomyosarcoma after an anthracycline-containing regimen1-3

Established in 6 open-label, single-arm trials, and 1 open-label, randomized, active-controlled clinical trial1

Find information about ordering YONDELIS® from specialty distributors

Considerations for treating unresectable or metastatic liposarcoma and leiomyosarcoma, 2 of the most common subtypes of soft tissue sarcoma4

A Janssen Oncology Representative ready to answer your questions about YONDELIS® is just a phone call away.

Locate a RepLocate a Rep




  1. YONDELIS® (trabectedin) [package insert]. Horsham, PA: Janssen Products, LP; 2017.
  2. HALAVEN® (eribulin) [package insert]. Woodcliff Lake, NJ: Eisai Inc.; 2016.
  3. VOTRIENT® (pazopanib) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2017.
  4. Toro JR, Travis LB, Wu HJ, Zhu K, Fletcher CDM, Devesa SS. Incidence patterns of soft tissue sarcomas, regardless of primary site, in the Surveillance, Epidemiology and End Results program, 1978–2001: an analysis of 26,758 cases. Int J Cancer. 2006;119(12):2922–2930.